PDCD1 and cancer: Our study showed irHAEs commonly occur in patients with cancer treated with a PD-1 or PD-L1 inhibitor (53.4% in KHMC; 46.3% in KHNMC) (Table 1), suggesting the imperative need for a prediction model to identify patients at a higher risk for developing irHAEs.